Novo Nordisk Prepares For European NovoRapid Launch
Executive Summary
Novo Nordisk is likely to begin European marketing in late 1999 for NovoRapid (insulin aspart) in diabetes mellitus, following a recommendation for approval by the Committee for Proprietary Medicinal Products at its May 18-20 plenary session.